BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 4055129)

  • 1. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China.
    Zeng Y; Zhang LG; Wu YC; Huang YS; Huang NQ; Li JY; Wang YB; Jiang MK; Fang Z; Meng NN
    Int J Cancer; 1985 Nov; 36(5):545-7. PubMed ID: 4055129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus seroepidemiology in China.
    Zeng Y; Pi GH; Deng H; Zhang JM; Wang PC; Wolf H; De Thé G
    AIDS Res; 1986 Dec; 2 Suppl 1():S7-15. PubMed ID: 3030349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China.
    Zeng Y; Zhang LG; Li HY; Jan MG; Zhang Q; Wu YC; Wang YS; Su GR
    Int J Cancer; 1982 Feb; 29(2):139-41. PubMed ID: 6895884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China.
    Zeng Y; Zhong JM; Li LY; Wang PZ; Tang H; Ma YR; Zhu JS; Pan WJ; Liu YX; Wei ZN
    Intervirology; 1983; 20(4):190-4. PubMed ID: 6317603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological survey of nasopharyngeal carcinoma in 21 cities of south China.
    Deng H; Zeng Y; Lei Y; Zhao Z; Wang P; Li B; Pi Z; Tan B; Zheng Y; Pan W
    Chin Med J (Engl); 1995 Apr; 108(4):300-3. PubMed ID: 7789220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.
    Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM
    Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
    Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gene engineering EB virus membrane antigen in detection of MA-IgA antibody--comparison with VCA-IgA and EA-IgA antibodies].
    Liu MZ
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):288-90. PubMed ID: 2176967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
    Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY
    Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A dynamic study on titer of EB virus VCA/IgA and EA/IgA in nasopharygeal carcinoma patients].
    Ji MF; Guo YQ; Liang JS; Zheng SA; Cheng WM; Yu BH; Ou XT; Wang DK
    Zhonghua Zhong Liu Za Zhi; 2003 May; 25(3):243-5. PubMed ID: 12839685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.